34 results about "Secretory IgA" patented technology

The invention provides a fusion protein and a porcine oral vaccine or medicine. The fusion protein is obtained by fusion of all or part of fragments of brucella outer membrane protein (OMP16) and porcine epidemic diarrhea virus S protein (PEDV-S). The porcine oral vaccine or medicine is obtained by steps: loading the fusion protein into a lactobacillus expression vector, transforming the lactobacillus expression vector into a Lactobacillus casei standard strain, and culturing the strain. The porcine oral vaccine is capable of effectively stimulating intestinal local immune cells to generate secretory IgA and is applicable to elimination of intestinal mucosal pathogens such as bacteria, viruses and parasites, and defects that conventional vaccination causes stress and antibodies fail to reach positions of the pathogens are avoided. In addition, due to adoption of an active lactobacillus vector system, possibility of degradation and ineffectiveness of inactivated vaccines before reaching small intestine mucosa is avoided. The porcine oral vaccine and the medicine are effective in prevention and treatment of porcine epidemic diarrhea virus infection.

A composition for treating a subject is provided. The composition includes dimeric or polymeric secretory IgA therapeutic. Formulating agents are mixed with the dimeric or polymeric secretory IgA to yield a dosing form of a capsule, tablet, and a suppository. A process for manufacturing a medicament for the treatment of C. difficile associated disease in a human is also provided that the modification of dimeric or polymeric IgA with secretory component to form a dimeric or polymeric secretory IgA therapeutic. The dimeric or polymeric secretory IgA therapeutic is then mixed with formulating agents to create a capsule, tablet, or suppository dosing form. The therapeutic is amenable to enrobement directly through microencapsulation or the dosing form is coated with an enteric coating. A method of C. difficile treatment with the therapeutic is also provided that is amenable to supplementation with concurrent or prior antibiotic administration.

The invention relates to heterologous protein secreted in bacillus subtilis in a non-classical path and application thereof to protein secretory expression. Carrying no signal peptide or secretory signals, D-allulose3-epimerase RDPE from Ruminococcus sp.5-139B-FAA can be secreted out of cells in quantity; it is proved through experiments that RDPE is not secreted in an Sec or Tat path or leaked out of the cells due to cell autolysis and lysis. Therefore RDPE is non-classical secretory protein in the bacillus subtilis. RDPE is respectively fused with 18 kinds of target protein, an attempt is made to use RDPE as export signals for achieving secretory expression of the target protein, 16 kinds of fused protein are obviously expressed in the cells, 9 kinds of fused protein are successfully secreted out of the cells, and the secretion level of two kinds of fused protein accounts for more than 50% of the corresponding total protein. Therefore, a new strategy for achieving protein secretory expression in the bacillus subtilis is developed.

The present invention relates to a kind of composition containing plant lactobacillus LP-Onlly strain and its application in strengthening intestinal immunobarrier. The composition of the present invention can intervene the homing of intestinal lymphocyte, control the number of intestinal tract secretive IgA and intestinal lymphocyte, lower the endotoxin level, improve intestinal tract immunobarrier and prevent damage of intestinal tract immunobarrier caused by hunger, malnutrition, infection, etc, and prevent and treat intestinal inflammation, infectious diseases and immune disorder diseases.

Described herein is secretory IgA isolated from the intestinal luminal fluid and intestinal mucosal of animals such as pigs and cows. Also included are methods of isolating secretory IgA. The secretory IgA is useful in food compositions such as animal and human food compositions as well as pharmaceutical compositions to increase growth rate, improve feed efficiency, reduce gastrointestinal inflammation, reduce a risk of gastrointestinal infection in the animal, or a combination thereof.

Described herein are methods of preventing and/or treating inflammation in a barrier surface structure in an individual in need thereof by orally administering to the individual an anti-inflammatory amount of secretory IgA.

The invention provides an expression vector, a lentivirus, a transgenic cell, a secretory antibody and a therapeutic composition for treating cancer. The expression vector carries the following nucleic acid molecules: a first nucleic acid molecule, which is used for encoding a secretory immune checkpoint inhibiting molecule fragment; optionally, a second nucleic acid molecule is further carried, wherein the second nucleic acid molecule is used for encoding a non-functional EGFR. The expression vector of the embodiment of the invention is introduced into receptor cells, a secretory anti-immunecheckpoint antibody is efficiently expressed in the receptor cells and secreted outside the cells, and an immune escape mechanism mediated by the immune checkpoint is repressed. When the expression vector of the embodiment of the invention is introduced into the receptor cells, such as lymphocytes, the specific killing of tumor cells by lymphocytes is strong and effective.

The invention belongs to the technical field of biology and provides an extraction method of human body secretory IgA, the human body secretory IgA, and an O-glycosylation measurement method thereof. The extraction method includes the steps of: firstly extracting oral cavity secretion of human body and centrifuging the oral cavity secretion; treating the oral cavity secretion to separate and purify the human body secretory immune globulin IgA by means of fast protein liquid chromatography with a Jacalin-agarose affinity chromatographic column; and performing the O-glycosylation measurement to the purified IgA. The method, compared with serum extraction, is painless, is convenient and is harmless to human body, and compared with urine IgA extraction, is high in content of the IgA after extraction and purification and is simple in separation and enrichment. The method can be widely applied in medical researching and laboratory researching.

The invention discloses preparation of a pig secretory IgA secretory component and a purification and renaturation method of the pig secretory IgA secretory component. SIgA is an important index for evaluating the mucosal immunity level of an organism, a secretory component SC is a specific component of an SIgA molecule, and the content of SIgA can be evaluated by virtue of SC proteins. Researching results on different prokaryotic expression vectors and host strains prove that by utilizing pET-28a prokaryotic expression vectors and Rosetta host strains, a large number of SC recombinant proteins can be expressed in vitro, after the SC recombinant proteins are purified and renaturated, the purities of the SC recombinant proteins are high, and the SC recombinant proteins can specifically bound with anti-nature SIgA polyclonal antibodies. The operation is simple, and a large number of the SC proteins with relatively high impurities can be acquired, so that the SC proteins have very good popularization and application values.

A nutritional composition comprises non-digestible oligosaccharideandnon-replicating Bifidobacterium breveand/or Streptococcus thermophilussynergistically stimulates secretory IgA in infants.

A method of inhibiting or treating infection by Coronaviridae virus of a susceptible host is provided that includes the administration of immune anti-Coronaviridae secretory IgA having a recombinant secretory component to at least one of tissue of the susceptible host. The administration being prior to, or after the susceptible host is exposed to the Coronaviridae virus. A composition for such administration is also provided.

A fermented formula comprising non digestible oligosaccharides synergistically stimulates secretory IgA in infants.

The invention is in the field of therapy of antibody deficiencies. Inventors demonstrate for the first time in both controls and IgA-deficient patients, systemic anti-microbiota IgG responses correlate with reduced inflammation suggesting that systemic IgG responses contribute to the gut microbiota confinement. Furthermore, SIgAd-associated inflammation is inversely correlated with systemic anti-commensal IgG responses, which may thus serve as a second line of defense. Altogether, these data suggest that systemic IgG and intestinal IgA cooperate in different body compartments to limit systemic pro-inflammatory pathways. As selective IgA deficient patients harbour elevated seric anti-commensal IgG levels, these findings suggest that in selective IgA deficiency, microbiota confinement is obtained at the price of a strong inflammatory response. Accordingly, the invention relates to a composition containing immunoglobulins A (IgA), more particularly secretory IgA, for use by oral administration in the prevention or treatment of antibody deficiencies such as SIgAd (Selective IgA deficiency) or common variable immunodeficiency (CVID) and associated inflammatory diseases.

The invention provides an African swine fever virus genetic engineering subunit oral vaccine, which comprises genetic engineering lactococcus lactis for recombinant expression of African swine fever virus antigen protein, and the antigen protein is ASFV p30 protein with an amino acid sequence of SEQ ID NO: 1, ASFV p54 protein with an amino acid sequence of SEQ ID NO: 3 or ASFV p72 protein with an amino acid sequence of SEQ ID NO: 5. The antigen protein is connected with an Escherichia coli heat-labile enterotoxin B subunit LTB gene protein. The African swine fever virus genetic engineering subunit oral vaccine can effectively stimulate local immune cells of intestinal tracts to generate secretory IgA, stimulate an organism to generate mucosal reaction, and further stimulate the organism to generate cellular immunity and humoral immunity through blood circulation.

Exercise is a stressor that is known to in some cases suppress antimicrobial protein levels, particularly secretory immunoglobulin type A (IgA). Athletes in the midst of in-season training often demonstrate low levels of sIgA and supplements may enhance post exercise mucosal immune function. A study was conducted where three treatments were administered (botanical spray, botanical drops, placebo) at the onset of 30 minutes of 80% V02 max cycle ergometer exercise. Secretory IgA and Human Alpha Defensin were quantified in saliva samples 30 minutes and 90 minutes post exercise. Analysis revealed a significant treatment effect at 30 min (p=0.030) with post hoc testing revealing a difference between the botanical spray and placebo (p=0.027), but by 90 minutes there was no differences by treatment (p=0.758). Based upon this study, it appears that a single dose of the tested botanical can provide enhanced mucosal immune capability for a short time post exercise.

The present invention relates to methods for producing compositions comprising secretory IgA and one or more probiotics. In particular, the invention relates to methods for producing compositions in which the secretory IgA and one or more probiotics are associated. The invention also relates to compositions obtainable by the methods and uses of the compositions, for example in reducing or preventing a non-viral infection and/or inflammation.